Valvular & structural heart diseaseCohort study

Hemodynamic Valve Deterioration After Transcatheter Aortic Valve Replacement

JACC Cardiovasc IntervPublished

  • Prospective registry cohort study
  • consecutive patients
  • case control-matched
  • Median follow-up 376 days (Q1-Q3: 365-1,825 days)

Authors' conclusion

HVD occurred in up to 1 in 4 patients throughout 10-year post-TAVR and was associated with a 5-fold increase in the risk of aortic valve reintervention.

Study context

Population
Consecutive patients undergoing transcatheter aortic valve replacement (TAVR) in the Bern TAVI registry, August 2007–June 2022matched cohort 155 vs 600
Participants
2,403 patients
Exposure
Hemodynamic valve deterioration (HVD) vs no HVD
  • HVDn = 155
  • no-HVDn = 600reference
Outcome
Cumulative incidence of moderate or severe HVD (VARC-3)
Follow-up
1, 5 and 10 years

Main finding

As reported in the abstract

Cumulative incidence of moderate or severe HVD

1 year

2.2% (95% CI 1.6%-3.1%)

5 years

10.8% (95% CI 9.2%-12.7%)

10 years

25.6% (95% CI 17.5%-36.5%)

Observational data: associations, not effects.

Further findings

OutcomeEstimateP value
Independent predictors of HVD — Aortic valve complex calcium volume vs no-HVDHR 1.81 (95% CI 1.11–2.97)P = 0.018
Independent predictors of HVD — Residual aortic regurgitation at discharge vs no-HVDHR 1.87 (95% CI 1.34–2.60)P < 0.001
Independent predictors of HVD — Treatment with oral anticoagulants vs no-HVDHR 1.78 (95% CI 1.00–3.15)P = 0.048
Clinical outcomes, case control-matched cohort · repeat aortic valve intervention · matched cohortRR 4.81 (95% CI 1.74–13.26)P = 0.001

Clinical outcomes, case control-matched cohort

Similar yearly rates of all-cause and CV mortality, and infective endocarditis

Original publication

Hemodynamic Valve Deterioration After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. Published 13 January 2025. doi:10.1016/j.jcin.2024.09.039

Summarised from the published abstract; every number is checked against it